Tatro Capital’s TG Therapeutics TGTX Stock Holding History

Tatro Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,000	Closed	-$208K	–	107
2020 Q4	$208K	Buy	+4,000	New	+$135K	0.19%	74

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Tatro Capital's TGTX Position: Q1 2021 in Review

Tatro Capital sold out of TG Therapeutics (TGTX) in Q1 2021, closing a stake of 4,000 shares — an estimated $208K sold.

Tatro Capital first reported a position in TGTX in Q4 2020 and held it in 1 quarter. The position peaked at $208K in Q4 2020. 240 funds tracked by Wall St. Rank hold TGTX as of Q1 2021.

Tatro Capital reported no remaining TG Therapeutics position as of Q1 2021 after selling out during the quarter.
Tatro Capital sold 4,000 TG Therapeutics shares in Q1 2021, an estimated $208K.
Tatro Capital first reported a position in TG Therapeutics in Q4 2020 and held it in 1 quarter.
Tatro Capital's TG Therapeutics position peaked at $208K in Q4 2020.
240 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2021.

Based on Tatro Capital's 13F filing for Q1 2021, filed 21 Apr 2021.